Downstream joint nbsp; North China pharmaceutical, Kyushu pass hand in hand, "nuggets"

Within maximum antibiotics class medicine products production enterprise North pharmaceutical and large modern medicine logistics enterprise Kyushu pass hand in hand established a subordinate company. this strong jointly of way is expected to implementation medicine production and distribution logistics of close combination. North pharmaceutical and Kyushu pass today align made notice said, on December 8, both signed has, decided established joint venture company, Kyushu pass to cash way to North pharmaceutical full funded subsidiaries China drug international increased funded. Kyushu pass increased funded Hou, North pharmaceutical holds China drug international 51% equity,　　Kyushu-China drug international 49% stake. capital increase and the amount will be confirmed by the choice of North China pharmaceutical, Kyushu pass a qualification assessment to assess the drug company's China International, reference of the assessment results, determined to increase capital amount. Pursuant to the cooperation agreement, both sides will work together into a Chinese medicine international to international pharmaceutical import and export business, domestic distribution in hospitals, hospital medicine distribution managed, based drug delivery, pharmaceutical distribution, Terminal distribution within the province,
Logistics services as the core business of medicine commercial enterprises. North pharmaceutical and Kyushu pass of cooperation may considered strong joint. information display, North pharmaceutical is by Hebei province for restructuring the approved, Yu on August 25, 1992 established of company limited. North pharmaceutical of core business is drug of research and development, and production and sales, currently has include medicine intermediate, and raw materials drug, and finished drug, zainei of near 600 a products rules products of production capacity and qualification. existing products to penicillin class, and head spore class, and vitamin class, bulk traditional chemical raw materials drug, and intermediate and the General drug preparations mainly, Antibiotics, vitamin c is the industry's leading enterprise. 2010 North China pharmaceutical sales revenue 10.287 billion yuan. Kyushu pass was approved by the Department of Commerce in Hubei Province, on November 28, 2008 by Kyushu pass set up by the group as a whole change co., Ltd. Kyushu pass is a mainly industrial investment and management of medicines and related health, drug